The 5th Edition of International Conference on Obesity and Chronic Diseases (ICOCD-2019 Berlin) witnessed attendees from 22 countries and concluded in Berlin, Germany on October 02, 2019. United Scientific Group (USG), A Nonprofit Organization.
Volume 3 Issue 2
Daniel Ta, Jerry T. Dang, Arya M. Sharma, Shahzeer Karmali and Renuca Modi
Liraglutide is a glucagon-like peptide-1 analogue approved for obesity management. In controlled clinical trials, high dose liraglutide (3.0 mg) has previously demonstrated efficacy and safety as a pharmacological option for weight loss in patients with obesity.
The 4th Edition of International Conference on Obesity and Chronic Diseases (ICOCD-2019) witnessed around 120 attendees from around the world and concluded in San Francisco on July 03, 2019.
The obesity epidemic is in the United States and world for past two decades. There is a link between obesity and chronic diseases development such as diabetes, cardiovascular disease, certain types of cancers and liver including non-alcoholic fatty liver disease (NAFLD).